Key parties involved are the Centers for Medicare & Medicaid Services (CMS), under the U.S. Department of Health and Human Services (HHS), in consultation with the HHS Office of Inspector General (HHS-OIG). Affected entities include DMEPOS suppliers in categories like orthotics personnel, pedorthic personnel, prosthetics personnel, prosthetic and orthotic personnel, registered pharmacists, and respiratory therapists; existing enrolled suppliers can continue billing and make minor changes, but circumvention risks denial, revocation, or penalties.[1][2][3][5]
The moratorium stems from CMS's program integrity concerns, citing fraud, waste, and abuse risks identified via enrollment data and OIG input, announced alongside the 2026 Home Health Prospective Payment System final rule that extended the 36-Month Rule to DMEPOS. Published in the Federal Register on February 27, 2026, per 42 C.F.R. § 424.570 and Social Security Act § 1866(j)(7), it lasts six months (potentially extendable) as part of broader anti-fraud shifts from "pay-and-chase" to preventive measures.[1][2][3][4][5][7][8]
Newsworthy due to its immediate impact on March 5, 2026 (headline date), disrupting new supplier entry and ownership deals amid rising Medicare fraud scrutiny, with warnings against misclassification and ties to transparency initiatives like public revocation disclosures. Affects sectors like sleep medicine practices offering PAP services; CMS may extend based on evaluations.[3][4][5][9]